Skip to main content

Long-Term Sulfonylurea Use Tied to Impaired Awareness of Hypoglycemia

Medically reviewed by Carmen Pope, BPharm. Last updated on July 24, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, July 23, 2024 -- The prevalence of impaired awareness of hypoglycemia (IAH) is high among patients using sulfonylureas long term, according to a study published in the July/August issue of the Annals of Family Medicine.

Hsiang-Ju Cheng, M.D., from the National Cheng Kung University in Tainan, Taiwan, and colleagues investigated the relationship between duration of medication use and prevalence of IAH among patients with insulin-treated or sulfonylurea-treated type 2 diabetes. Analysis included 898 patients (41.0 percent insulin users; 65.1 percent sulfonylurea users).

The researchers found that overall, IAH prevalence was 41.0 percent using the Gold questionnaire and 28.2 percent using the Clarke questionnaire among insulin users, and 65.3 and 51.3 percent, respectively, among sulfonylurea users. For sulfonylurea use, prevalence increased with longer duration, whereas it decreased with the duration of insulin use. Five or more years of sulfonylurea use was significantly associated with threefold increases in the odds of IAH, regardless of criteria used. Regular blood glucose testing and retinal examinations cut odds of IAH in both insulin and sulfonylurea users.

"The reasons for the differential association of hypoglycemia history with IAH between insulin users and sulfonylurea users need more study," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Link Between T2DM, Spinal Degenerative Disorder May Be Method-Dependent

TUESDAY, July 23, 2024 -- The association between type 2 diabetes mellitus (T2DM) and spinal degenerative disorders (SDDs) may be method-dependent, according to a study published...

2011 to 2023 Saw Increase in New GLP-1 Receptor Agonist Prescriptions

MONDAY, July 22, 2024 -- From 2011 to 2023, there was an increase in new glucagon like peptide 1 receptor agonist (GLP-1RA) prescriptions, according to a research letter published...

Irregular Sleep Duration Tied to Increased Risk for Developing Diabetes

FRIDAY, July 19, 2024 -- Irregular sleep duration is associated with elevated diabetes risk, according to a study published online July 17 in Diabetes Care. Sina Kianersi, Ph.D...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.